Discover how pharma companies in China are collaborating like never before to keep the supply chain from breaking, as well as asking the government to help address a flurry of issues laid bare by the public health crisis. Insights into these pressing issues and much more are detailed in the newly released China’s Challenges and Opportunities in the Wake of COVID-19 by Pharma Intelligence.
Rare peek into the policies behind the vaccines race
How China reacted to the deficiencies in primary healthcare exposed by COVID-19
The impact COVID-19 has had on pharmaceutical supply chains
How telecare and telemedicine are valued more than ever